Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Postoperative recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical
resection. To date, adjuvant chemotherapy or other adjuvant modalities have not been proven
effective in preventing or delaying recurrence. The aim of this prospective randomized study
was to evaluate the effectiveness of Thalidomide as a postoperative adjuvant regimen in
inhibiting the recurrence of HCC
Phase:
N/A
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University